1. Home
  2. ZTR vs INDP Comparison

ZTR vs INDP Comparison

Compare ZTR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Total Return Fund Inc.

ZTR

Virtus Total Return Fund Inc.

HOLD

Current Price

$6.81

Market Cap

342.5M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.46

Market Cap

350.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZTR
INDP
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
342.5M
350.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
ZTR
INDP
Price
$6.81
$2.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
154.5K
152.2K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.14
$0.92
52 Week High
$7.11
$10.91

Technical Indicators

Market Signals
Indicator
ZTR
INDP
Relative Strength Index (RSI) 49.87 45.44
Support Level $6.68 $2.42
Resistance Level $6.81 $3.11
Average True Range (ATR) 0.07 0.21
MACD -0.01 -0.06
Stochastic Oscillator 26.67 22.99

Price Performance

Historical Comparison
ZTR
INDP

About ZTR Virtus Total Return Fund Inc.

Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: